CS
RVMD icon

Credit Suisse’s Revolution Medicines RVMD Stock Holding History

Credit Suisse’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.62M Buy
112,301
+16,543
+17% +$490K ﹤0.01% 1481
2023
Q4 		$2.75M Buy
95,758
+22,145
+30% +$532K ﹤0.01% 1698
2023
Q3 		$2.04M Sell
73,613
-16,893
-19% -$501K ﹤0.01% 1829
2023
Q2 		$2.42M Buy
90,506
+20,606
+29% +$506K ﹤0.01% 1785
2023
Q1 		$1.51M Buy
69,900
+12,896
+23% +$318K ﹤0.01% 2046
2022
Q4 		$1.36M Buy
57,004
+1,130
+2% +$24K ﹤0.01% 2131
2022
Q3 		$1.1M Buy
55,874
+15,366
+38% +$338K ﹤0.01% 2258
2022
Q2 		$790K Sell
40,508
-4,672
-10% -$90.9K ﹤0.01% 2539
2022
Q1 		$1.15M Sell
45,180
-1,124
-2% -$24.5K ﹤0.01% 2456
2021
Q4 		$1.17M Buy
46,304
+14,151
+44% +$399K ﹤0.01% 3200
2021
Q3 		$884K Buy
32,153
+4,771
+17% +$139K ﹤0.01% 3440
2021
Q2 		$869K Buy
27,382
+11,641
+74% +$406K ﹤0.01% 3493
2021
Q1 		$723K Sell
15,741
-36,545
-70% -$1.64M ﹤0.01% 3530
2020
Q4 		$2.07M Buy
52,286
+29,698
+131% +$1.17M ﹤0.01% 2791
2020
Q3 		$787K Buy
22,588
+15,065
+200% +$417K ﹤0.01% 3106
2020
Q2 		$237K Buy
+7,523
New +$237K ﹤0.01% 3679

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Credit Suisse's RVMD Position: Q1 2024 in Review

Credit Suisse increased its Revolution Medicines (RVMD) stake by 17% in Q1 2024, buying an estimated $490K and bringing the position to 112,301 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

Credit Suisse first reported a position in RVMD in Q2 2020 and has held it in 16 quarters since. 210 funds tracked by Wall St. Rank hold RVMD as of Q1 2024.

  • Credit Suisse held 112,301 shares of Revolution Medicines worth $3.62M as of Q1 2024.
  • Credit Suisse bought 16,543 Revolution Medicines shares in Q1 2024, an estimated $490K.
  • Revolution Medicines made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1481 holding.
  • Credit Suisse first reported a position in Revolution Medicines in Q2 2020 and has held it in 16 quarters since.
  • 210 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.